RxDoctor Payments Data

Brad Dworkin, MD

Gastroenterology · Valhalla, NYNPI 1528170362

Payments from drug & device makers

$1,703in general payments, 2019–2025

Across 78 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$315
  • AbbVie$296
  • Johnson & Johnson$220
  • Bristol Myers Squibb$156
  • Covidien LP$145
  • AstraZeneca$68
  • plus $501 from 17 others

What the payments were for

  • Food & beverage$1,63596%
  • Education$684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,703 in reported general payments places this provider in the 45th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$100,403
Medicare patients
246
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab15$127,914
ZenpepLipase/Protease/Amylase44$92,218
LinzessLinaclotide108$80,432
XifaxanRifaximin23$59,495
SancusoGranisetron11$49,665
MotegrityPrucalopride Succinate45$35,181
CreonLipase/Protease/Amylase18$29,768
ErythromycinErythromycin Base16$16,838
VoqueznaVonoprazan Fumarate13$10,350
Sucralfate54$7,268
Ondansetron OdtOndansetron66$4,805
Famotidine214$4,277
Mesalamine21$3,405
Diphenhydramine Hcl75$3,234
Pantoprazole Sodium208$3,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity$315$163,09660 claims
AbbVieLinzess, Creon$296$110,200126 claims
Aimmune Therapeutics, Inc.Zenpep$41$92,21844 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$28$59,49523 claims
Phathom Pharmaceuticals, Inc.Voquezna$21$10,35013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Valhalla

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →